Clinical Trial Update: Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of niraparib, abiraterone acetate, and prednisone for metastatic hormone-sensitive prostate cancer with deleterious H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Niraparib (Niraparib)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Qian Qin | Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation | Phase 2 | Status: WITHDRAWN